[en] Background: Sub-Saharan Africans exhibit a higher frequency of chronic kidney disease (CKD) than other populations. In this study, we sought to determine the frequency of apolipoprotein L1 (APOL1) genotypes in hypertension-attributed CKD in Kinshasa, Democratic Republic of the Congo. Methods: We performed a case-control study identifying 162 subjects: 79 with hypertension-attributed CKD and 83 controls living in Kinshasa who were genotyped for APOL1 risk variants between July 2013 and November 2016. We selected control subjects from the general population and matched them with the cases according to age. Logistic regression analysis was used to examine the relationship between APOL1 high-risk genotypes and CKD. Results: The frequencies of the APOL1 G1 and G2 alleles were 19.1 and 7.1%, respectively. The number of individuals with the G1 and G2 risk alleles was significantly higher in the CKD group (12.7%) than in the control group (2.4%), particularly in individuals with end-stage kidney disease (14.3%). Subjects carrying two risk alleles was strongly and independently associated with hypertension-attributed nephropathy, with an adjusted odds ratio of 7.7 (95% confidence interval 1.5-39.7; P = 0.014). The high-risk APOL1 genotypes were G1/G1 and G1/G2, whereas G2/G2 was not found in the study population. Conclusions: The results of this study demonstrate the association of high-risk APOL1 genotypes with kidney disease in Kinshasa. The absence of G2/G2 may be consistent with powerful selective sweeps induced by Trypanosoma brucei gambiense infection. In contrast, the presence of APOL1 G2/G2 among individuals of African ancestry in the USA may indicate relaxation of natural selection in a trypanosome-free environment.
Disciplines :
Laboratory medicine & medical technology Urology & nephrology
Author, co-author :
Sumaili, Ernest K.
Shemer, Revital
Kruzel-Davila, Etty
Cohen, Eric P.
Mutantu, Pierre N.
Bukabau, Justine B.
Makulo, Jean Robert R.
Mokoli, Vieux M.
Luse, Jeannine L.
Pakasa, Nestor M.
Cavalier, Etienne ; Université de Liège - ULiège > Département de pharmacie > Chimie médicale
Genovese G, Friedman DJ, Ross MD et al. Association of trypanolytic APOL1 variants with kidney disease in African Americans. Science 2010; 329: 841-845
Tzur S, Rosset S, Shemer R et al. Missense mutations in the APOL1 gene are highly associated with end stage kidney disease risk previously attributed to the MYH9 gene. Hum Genet 2010; 128: 345-350
Kopp JB, Nelson GW, Sampath K et al. APOL1 genetic variants in focal segmental glomerulosclerosis and HIV-associated nephropathy. J Am Soc Nephrol 2011; 22: 2129-2137
Kasembeli AN, Duarte R, Ramsay M et al. APOL1 risk variants are strongly associated with HIV-associated nephropathy in Black South Africans. J Am Soc Nephrol 2015; 26: 2882-2890
Vanhamme L, Paturiaux-Hanocq F, Poelvoorde P et al. Apolipoprotein L-I is the trypanosome lytic factor of human serum. Nature 2003; 422: 83-87
Osafo C, Raji YR, Olanrewaju T et al. Genomic approaches to the burden of kidney disease in Sub-Saharan Africa: The Human Heredity and Health in Africa (H3Africa) Kidney Disease Research Network. Kidney Int 2016; 90: 2-5
Thomson R, Genovese G, Canon C et al. Evolution of the primate trypanolytic factor APOL1. Proc Natl Acad Sci USA 2014; 111: E2130-E2139
Cooper A, Ilboudo H, Alibu VP et al. APOL1 renal risk variants have contrasting resistance and susceptibility associations with African trypanosomiasis. Elife 2017; 6; e25461: 1-18
KaboréJW, Ilboudo H, Noyes H et al. Candidate gene polymorphisms study between human African trypanosomiasis clinical phenotypes in Guinea. PLoS Negl Trop Dis 2017; 11: E0005833
Franco JR, Cecchi G, Priotto G et al. Monitoring the elimination of human African trypanosomiasis: Update to 2014. PLoS Negl Trop Dis 2017; 11: E0005585
Sumaili EK, Cohen EP, Zinga CV et al. High prevalence of undiagnosed chronic kidney disease among at-risk population in Kinshasa, the Democratic Republic of Congo. BMC Nephrol 2009; 10: 18
Nlandu Y, Lepira F, Makulo JR et al. Reverse epidemiology of elevated blood pressure among chronic hemodialysis black patients with stroke: A historical cohort study. BMC Nephrol 2017; 18: 277
Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252
Levey AS, Stevens LA, Schmid CH et al. A new equation to estimate glomerular filtration rate. Ann InternMed 2009; 150: 604-612
Omuse G, Maina D, Mwangi J et al. Comparison of equations for estimating glomerular filtration rate in screening for chronic kidney disease in asymptomatic black Africans: A cross sectional study. BMC Nephrol 2017; 18: 369
Bukabau JB, Sumaili EK, Cavalier E et al. Performance of glomerular filtration rate estimation equations in Congolese healthy adults: The inopportunity of the ethnic correction. PLoS One 2018; 13: E0193384
Levey AS, Atkins R, Coresh J et al. Chronic kidney disease as a global public health problem: Approaches and initiatives-A position statement from Kidney Disease Improving Global Outcomes. Kidney Int 2007; 72: 247-259
Miller SA, Dykes DD, Polesky HF. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988; 16: 1215
Ulasi II, Tzur S, Wasser WG et al. High population frequencies of APOL1 risk variants are associated with increased prevalence of non-diabetic chronic kidney disease in the Igbo people from south-eastern Nigeria. Nephron Clin Pract 2013; 123: 123-128
Limou S, Nelson GW, Lecordier L et al. Sequencing rare and common APOL1 coding variants to determine kidney disease risk. Kidney Int 2015; 88: 754-763
Hawkins GA, Friedman DJ, Lu L et al. Re-sequencing of the APOL1-APOL4 and MYH9 gene regions in African Americans does not identify additional risks for CKD progression. Am J Nephrol 2015; 42: 99-106
Skorecki KL, Wasser WG. Hypertension-misattributed kidney disease in African Americans. Kidney Int 2013; 83: 6-9
Alves I, Coelho M, Gignoux C et al. Genetic homogeneity across Bantu-speaking groups from Mozambique and Angola challenges early split scenarios between East and West Bantu populations. Hum Biol 2011; 83: 13-38
Nielsen R, Akey JM, JakobssonMet al. Tracing the peopling of the world through genomics. Nature 2017; 541: 302
Samanovic M, Molina-Portela MP, Chessler AD et al. Trypanosome lytic factor, an antimicrobial high-density lipoprotein, ameliorates Leishmania infection. PLoS Pathog 2009; 5: E1000276
Taylor HE, Khatua AK, Popik W. The innate immune factor apolipoprotein L1 restricts HIV-1 infection. J Virol 2014; 88: 592-603
Tzur S, Rosset S, Skorecki K et al. APOL1 allelic variants are associated with lower age of dialysis initiation and thereby increased dialysis vintage in African and Hispanic Americans with non-diabetic end-stage kidney disease. Nephrol Dial Transplant 2012; 27: 1498-1505
Kanji Z, Powe CE, Wenger JB et al. Genetic variation in APOL1 associates with younger age at hemodialysis initiation. J Am Soc Nephrol 2011; 22: 2091-2097
Karczewski KJ, Weisburd B, Thomas B et al. The ExAC browser: Displaying reference data information from over 60 000 exomes. Nucleic Acids Res 2017; 45: D840-D845
